394 related articles for article (PubMed ID: 35815933)
21. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
Pérez-Then E; Lucas C; Monteiro VS; Miric M; Brache V; Cochon L; Vogels CBF; Malik AA; De la Cruz E; Jorge A; De Los Santos M; Leon P; Breban MI; Billig K; Yildirim I; Pearson C; Downing R; Gagnon E; Muyombwe A; Razeq J; Campbell M; Ko AI; Omer SB; Grubaugh ND; Vermund SH; Iwasaki A
Nat Med; 2022 Mar; 28(3):481-485. PubMed ID: 35051990
[TBL] [Abstract][Full Text] [Related]
22. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
[No Abstract] [Full Text] [Related]
23. Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol.
Campos GRF; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; de Assis JV; Silva TBS; Alves PA; Fernandes GDR; de Oliveira JG; Rahal P; Grenfell RFQ; Nogueira ML
Front Cell Infect Microbiol; 2024; 14():1371695. PubMed ID: 38638823
[TBL] [Abstract][Full Text] [Related]
24. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
[TBL] [Abstract][Full Text] [Related]
25. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
26. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
Evans JP; Zeng C; Qu P; Faraone J; Zheng YM; Carlin C; Bednash JS; Zhou T; Lozanski G; Mallampalli R; Saif LJ; Oltz EM; Mohler PJ; Xu K; Gumina RJ; Liu SL
Cell Host Microbe; 2022 Aug; 30(8):1093-1102.e3. PubMed ID: 35526534
[TBL] [Abstract][Full Text] [Related]
27. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies.
Tada T; Zhou H; Dcosta BM; Samanovic MI; Chivukula V; Herati RS; Hubbard SR; Mulligan MJ; Landau NR
EBioMedicine; 2022 Apr; 78():103944. PubMed ID: 35465948
[TBL] [Abstract][Full Text] [Related]
28. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies.
Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P
Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies.
Lusvarghi S; Pollett SD; Neerukonda SN; Wang W; Wang R; Vassell R; Epsi NJ; Fries AC; Agan BK; Lindholm DA; Colombo CJ; Mody R; Ewers EC; Lalani T; Ganesan A; Goguet E; Hollis-Perry M; Coggins SA; Simons MP; Katzelnick LC; Wang G; Tribble DR; Bentley L; Eakin AE; Broder CC; Erlandson KJ; Laing ED; Burgess TH; Mitre E; Weiss CD
Sci Transl Med; 2022 May; 14(645):eabn8543. PubMed ID: 35380448
[TBL] [Abstract][Full Text] [Related]
30. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
31. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y
Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446
[TBL] [Abstract][Full Text] [Related]
32. Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose.
Sanna G; Marongiu A; Firinu D; Piras C; Palmas V; Galdiero M; Atzori L; Caria P; Campagna M; Perra A; Costanzo G; Coghe F; Littera R; Chessa L; Manzin A
Clin Exp Med; 2024 Jan; 24(1):12. PubMed ID: 38244064
[TBL] [Abstract][Full Text] [Related]
33. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
[TBL] [Abstract][Full Text] [Related]
34. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
35. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
Assawakosri S; Kanokudom S; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Yorsaeng R; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Honsawek S; Poovorawan Y
J Infect Dis; 2022 Oct; 226(8):1372-1381. PubMed ID: 35267040
[TBL] [Abstract][Full Text] [Related]
36. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
37. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD;
Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254
[TBL] [Abstract][Full Text] [Related]
38. Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.
Laquintana V; Mottini C; Marchesi F; Marcozzi B; Terrenato I; Sperandio E; de Latouliere L; Carrieri F; Pimpinelli F; Pontone M; Pellini R; Campo F; Conti L; Accetta C; Mandoj C; Petrone F; Di Bella O; Vujovic B; Morrone A; Compagnone M; Principato E; Pinto E; Papa E; Falcucci P; La Malfa A; Pallocca M; De Marco F; Piaggio G; Ciliberto G; Mengarelli A; di Martino S
Front Immunol; 2023; 14():1221587. PubMed ID: 38343436
[TBL] [Abstract][Full Text] [Related]
39. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
[TBL] [Abstract][Full Text] [Related]
40. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]